Hoth Therapeutics Inc (NASDAQ:HOTH) was the recipient of a significant growth in short interest in the month of September. As of September 30th, there was short interest totalling 25,600 shares, a growth of 65.2% from the August 30th total of 15,500 shares. Based on an average trading volume of 12,700 shares, the short-interest ratio is currently 2.0 days. Approximately 0.7% of the shares of the company are short sold.
Shares of Hoth Therapeutics stock remained flat at $$4.20 during trading hours on Friday. The stock had a trading volume of 3,670 shares, compared to its average volume of 11,864. Hoth Therapeutics has a 52-week low of $3.83 and a 52-week high of $13.88. The business has a 50 day moving average price of $4.84 and a two-hundred day moving average price of $5.38. The company has a market cap of $42.29 million and a price-to-earnings ratio of -8.39.
Hoth Therapeutics (NASDAQ:HOTH) last posted its quarterly earnings results on Wednesday, August 14th. The company reported ($0.13) EPS for the quarter. Research analysts forecast that Hoth Therapeutics will post -0.39 EPS for the current year.
Hoth Therapeutics, Inc, a development stage biopharmaceutical company, focuses on developing targeted therapeutics for atopic dermatitis. It intends to use the BioLexa Platform to develop 2 topical cream products that treat eczema and reduces post-procedure infections for patients undergoing aesthetic dermatology procedures.
Featured Article: LIBOR
Receive News & Ratings for Hoth Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hoth Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.